Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is a humanized IgG4 monoclonal antibody that targets IL-17? and prevents the interaction with its receptor (IL-17R), thus blocking IL-17? mediated inflammatory and immune responses. IL-17? is known to play an important role in autoimmune diseases such as rheumatoid arthritis and plaque psoriasis. The monoclonal antibody is produced in CHO cells using recombinant DNA technology. It consists of two identical light chains of 219 amino acids each and two identical heavy chains of 445 amino acids each. The original monoclonal antibody received approval from the FDA for the treatment of adults suffering from moderate-to-severe psoriasis and psoriatic arthritis
Biovision | A2149 | Anti-IL-17? (Ixekizumab), Humanized Antibody DataSheet
Antibody Target: IL-17?
Target Alternative Name: IL17a, IL17, CTLA8, IL-17, CTLA-8, IL-17A
Tag Line: A humanized monoclonal antibody that specifically targets IL-17? and inhibits IL-17? mediated inflammatory responses
Category: Biosimilars
Host: Recombinant
Isotype: IgG4, kappa
Species Reactivities: Human
Immunogen Sequence: Human IL-17?
Accession #: DB11569
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
